[Ketamine and esketamine in treatment-resistant depression - Pharmacological effects and augmented psychotherapy].
Fortschr Neurol Psychiatr May 13, 2026 Cornelius Schüle, Anna Sobieraj, Helena Rogg 1 citation
Abstract: Esketamine is an NMDA receptor antagonist and was approved as a nasal spray in March 2019, initially in the USA and then in December 2019 in Europe, as an adjunct to antidepressant pharmacotherapy for the treatment of treatment-resistant major depression or for rapid symptom reduction in psychiatric emergency situations in patients with major depression. In addition, esketamine nasal...